Becton Dickinson to Invest $19 Billion in US Manufacturing

Becton Dickinson (BDX) reported positive 9-month results from its AGILITY trial for the Revello Vascular Covered Stent, meeting its primary endpoint. The company has seen a 20.28% share price increase over 90 days, despite a 6.25% year-to-date decline. Analysts suggest the stock is 7% undervalued at $182.75, with a fair value estimate of $195.67. Recent developments include a U.S. manufacturing partnership, leadership changes, and a product recall.

Becton, Dickinson and Company (BD) reported nine-month data from the AGILITY trial of its Revello Vascular Covered Stent, showing a 2.8% failure rate for the primary endpoint in iliac artery disease patients. The trial met its safety and effectiveness goals, with 97.2% primary patency and 98.3% freedom from revascularization. The stent is CE-marked in Europe but remains investigational in the US. BD aims to further characterize the stent's performance as follow-up continues.

BD (BDX) reported nine-month results from the iliac cohort of the AGILITY trial for its Revello Vascular Covered Stent, meeting primary endpoints with a 2.8% failure rate. The study showed 97.2% primary patency and 98.3% freedom from revascularization, with no device-related deaths. The stent is CE marked but investigational in the U.S. BD completed enrollment in the study’s superficial femoral and proximal popliteal artery cohort in August.

BD (NYSE: BDX) reported positive nine-month results from the AGILITY trial for its Revello™ Vascular Covered Stent, showing high vessel patency and low reintervention rates in treating iliac artery disease. The study met its primary endpoint with a 2.8% failure rate, and patients showed improved mobility and symptoms. The trial is ongoing, with follow-up through 36 months. The device is CE marked but remains investigational in the U.S.

Becton, Dickinson and Company (BDX) announced a $19 billion investment to expand U.S. medical manufacturing, partnering with the U.S. government. The plan includes $3 billion for facility expansions and aims to increase domestic production of medical consumables by 5 billion units annually. The company will use American steel for all needles and is exempt from future Section 232 tariffs on specified products. BDX shares rose 2.06% to $184.38 on the news.

Becton Dickinson agreed to invest $19 billion in the U.S. over several years, including $3 billion for expanding domestic manufacturing, in exchange for future tariff relief. The company plans to increase U.S. production of medical consumables and needles, aiming for 80% domestic supply. President Trump announced medical device tariffs by year-end. The financial impact of the deal is not yet quantified.